READ OUR 2025 REPORT TO READERS

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

4.260 +0.280 (+7.04%)
Streaming Delayed Price Updated: 10:36 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
News headline image
Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial ↗
 
Via Benzinga
News headline image
Can Fite Biofarma: Q1 Earnings Insights ↗
Can Fite Biofarma (AMEX:CANF) reported its Q1 earnings results on Thursday, May 26, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday ↗
Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media. 
Via Benzinga
News headline image
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday ↗
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
News headline image
Aspen Aerogels And 28 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday ↗
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering. 
Via Benzinga
News headline image
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2 ↗
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1... 
Via Benzinga
News headline image
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Granted Key NASH Patent in Israel
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis? ↗
Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports Revenue Growth In 2021, Provides Clinical Update ↗
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI) announced 
Via Benzinga
News headline image
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Can-Fite Reports 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX ↗
Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF)... 
Via Benzinga
News headline image
Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study ↗
Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson... 
Via Benzinga
News headline image
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor? ↗
Photo by Diana Polekhina on Unsplash 
Via Benzinga
News headline image
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article